Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn more about the challenges in NSCLC treatment, how proteomics-based analysis could enable personalized cancer treatments and the advantages of a test to predict a patient’s clinical benefit from PD-1/PD-L1 inhibitors.

Read more here.